Temporal effects of testosterone propionate injections on serum lipoprotein concentrations in rats

Medicine and Science in Sports and Exercise

Volumn 31, Issue 5, 1999, Pages 664-669

  Frisch, Frank ^a   Sumida, Ken D ^a  

^a CHAPMAN UNIVERSITY   (United States)

Author keywords

Androgenic anabolic steroid; HDL; LDL; Testicular atrophy; Total cholesterol; Triacylglycerols

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE PROPIONATE;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG ABUSE; DRUG EFFECT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; RAT; SPORT;

ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; INJECTIONS; LIPOPROTEINS; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TESTIS; TESTOSTERONE; TIME FACTORS;

EID: 0032913116     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005768-199905000-00007     Document Type: Article

References (33)

1. ALLAIN, C. A., L. S. POON, C. S. G. CHAN, W. RICHMOND, and P. C. FU. Enzymatic determination of total serum cholesterol. Clin. Chem. 20:470-475, 1974.
2. ANDERSON, P. M. and M. A. SORENSON. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet. 27:19-31, 1994.
3. ANDERSON, R. A. and F. C. WU. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J. Clin. Endocrinol. Metab. 81:896-901, 1996.
4. APPLEBAUM-BOWDEN, D., S. M. HAFFNER, and W. R. HAZZARD. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in HDL cholesterol. Metabolism 36:949-952, 1987.
5. 2. Clin. Chem. 29:2026-2030, 1983.
6. BAGATELL, C. J. and W. J. BREMMER. Androgen and progestagen effects on plasma lipids. Prog. Cardiovasc. Dis. 38:255-271, 1995.
7. BAGATELL, C. J., J. R. HEIMAN, A. M. MATSUMOTO, J. E. RIVIER, and W. J. BREMNER. Metabolic and behavioral effects of high dose, exogenous testosterone (T) in normal men. J. Clin. Endocrinol. Metab. 79:561-567, 1994.
8. BALDO-ENZI, G., F. GIADA, G. ZULIANI, et al. Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids. Metabolism 39:203-208, 1990.
9. BENGHUZZI, H. A., P. K. BAJPAI, and B. G. ENGLAND. The delivery of testosterone and dihydrotestosterone by ALCAP ceramic implants in rats. J. Invest. Surg. 3:197-215, 1990.
10. BHASIN, S., T. W. STORER, N. BERMAN, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 336:1-7, 1996.
11. CASTELLI, W. P., R. J. GARRISON, P. W. F. WILSON, R. D. ABBOTT, S. KALOUSDIAN, and W. B. KANNEL. Incidence of coronary heart disease (CHD) and lipoprotein cholesterol levels: the Framingham Study. JAMA 256:2835-2838, 1986.
12. COHEN, L. I., C. G. HARFORD, and G. G. ROGERS. Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med. Sci. Sports Exerc. 28:176-179, 1996.
13. COSTILL, D. L., D. R. PEARSON, and W. J. FINK. Anabolic steroid use among athletes: changes in HDL-C levels. Physician Sport-med. 12:113-117, 1984.
14. COWART, V. Steroids in sports: after four decades, time to return these genies to bottle? JAMA 257:421-429, 1987.
15. CROOK, D., M. SIDHU, M. SEED, M. O'DONNELL, and J. C. STEVENSON. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 92:41-47, 1992.
16. FRIEDEWALD, W. T., R. I. LEVY, and D. S. FREDRICKSON. Estimation of the concentration of LDL cholesterol without the use of the preparative ultracentrifuge. Clin. Chem. 18:499-502, 1972.
17. FRIEDL, K. E., C. J. HANNAN, R. E. JONES, and S. R. PLYMATE. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 39:69-74, 1990.
18. GAO, Y. and R. V. SHORT. Use of an estrogen, androgen, or gestagen as a potential chemosterilant for control of rat and mouse populations. J. Reprod. Fertil. 97:39-49, 1993.
19. GLAZER, G. Atherogenic effects of anabolic steroids on serum lipid levels. Arch. Intern. Med. 151:1925-1933, 1991.
20. GLAZER, G. and A. L. SUCHMAN. Lack of demonstrated effect of nandrolone on serum lipids. Metabolism 43:204-210, 1994.
21. GLUECK, C. J. Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. Am. Heart J. 110:1107-1115, 1985.
22. HONG, M. K., P. A. ROMM, K. REAGAN, C. E. GREEN, and C. E. RACKLEY. Usefulness of the total cholesterol to HDL cholesterol ratio in predicting angiographic coronary artery disease in women. Am. J. Cardiol. 68:1646-1650, 1991.
23. LAMB, D. R. Anabolic steroids in athletics: how well do they work and how dangerous are they? Am. J. Sports Med. 12:31-38, 1984.
24. LEEDS, E. M., J. E. WILKERSON, G. D. BROWN, G. KAMEN, and D. BREDLE. Effects of exercise and anabolic steroids on total and lipoprotein cholesterol concentrations in male and female rats. Med. Sci. Sports Exerc. 18:663-667, 1986.
25. LUKAS, S. E. Current perspectives on anabolic-androgenic steroid abuse. Trends Pharmacol. Sci. 14:61-68, 1993.
26. MATTIE, H. Clinical pharmacokinetics of aztreonam. An update. Clin. Pharmacokinet. 26:99-106, 1994.
27. MCGOWAN, M. W., J. D. ARTISS, D. R. STRANDBERGH, and B. ZAK. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin. Chem. 29:538-542, 1983.
28. MELCHERT, R. B. and A. A. WELDER. Cardiovascular effects of androgenic-anabolic steroids. Med. Sci. Sports Exerc. 27:1252-1262, 1995.
29. MILLER, N. D. Associations of high-density lipoprotein sub-classes and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113:589-597,1987.
30. THOMPSON, P. D., E. M. CULLINANE, S. P. SADY, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261:1165-1168, 1989.
31. WEYRICH, A. S., W. J. REJESKI, P. H. BRUBAKER, and J. S. PARKS. The effects of testosterone on lipids and eicosanoids in cynomolgus monkeys. Med. Sci. Sports Exerc. 24:333-338, 1992.
32. ZMUDA, J. M. M. C. FAHRENBACH, B. T. YOUNKIN, et al. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metabolism 42:446-450, 1993.
33. ZULIANI, U., B. BERNARDINI, A. CATAPANO, M. CAMPANA, G. CERIOLI, and M. SPATTINI. Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders. Int. J. Sports Med. 10:62-66, 1988.